Compounds > 2-amino-5,6-dihydroxytetralin
Page last updated: 2024-12-06

2-amino-5,6-dihydroxytetralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-amino-5,6-dihydroxytetralin, also known as 2-amino-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene, is a synthetic compound with a complex structure and potential biological activity. It has been investigated for its potential as a neurotransmitter and its involvement in various biological processes, including dopamine receptor agonism, neuroprotection, and anti-inflammatory effects. While studies are ongoing to understand its full range of effects, it is believed to be involved in neurodegenerative diseases, mental health conditions, and pain perception. The compound has been synthesized through various synthetic routes, involving multistep chemical reactions. However, research on 2-amino-5,6-dihydroxytetralin is still in its early stages, and further investigation is required to fully elucidate its potential therapeutic applications and safety profile.'

2-amino-5,6-dihydroxytetralin: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID37631
CHEMBL ID163912
SCHEMBL ID4263745
MeSH IDM0073711

Synonyms (16)

Synonym
PDSP1_000479
PDSP2_000477
5,6-adtn
6-amino-5,6,7,8-tetrahydronaphthalene-1,2-diol
CHEMBL163912 ,
bdbm50028970
6-amino-5,6,7,8-tetrahydro-naphthalene-1,2-diol
2-amino-5,6-dihydroxy-1,2,3,4-tetrahydronaphthalene
21489-74-7
2-amino-5,6-dihydroxytetralin
6-amino-5,6,7,8-tetrahydro-1,2-naphthalenediol
SCHEMBL4263745
5,6-dihydroxy-2-aminotetralin
FT-0744995
DTXSID90944085
PD033609
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki15.48330.00001.372610.0000AID1803082
Carbonic anhydrase 2Homo sapiens (human)Ki15.48330.00000.72369.9200AID1803082
Tryptophan 5-hydroxylase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.70000.03801.30806.4300AID64453
Carbonic anhydrase 6Homo sapiens (human)Ki15.48330.00011.47109.9200AID1803082
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.70000.00010.54948.4000AID64453
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID57846Cardioselectivity expressed as change in blood pressure for 50% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1136162Agonist activity at Wistar rat brain cholinergic transporter assessed as tritium efflux by measuring [3H]choline release at 2 uM after 20 to 30 mins by liquid scintillation counting analysis relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID58657Ionotropic selectivity expressed as change in heart rate for 100 percent increase in right ventricular contractile force in dogs; CF(100) levels not obtained1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1136159Agonist activity at Wistar rat cortex dopamine transporter assessed as tritium efflux by measuring [3H]noradrenaline release at 2 uM after 20 mins by liquid scintillation counting analysis relative to total tissue content1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID60583Inotropic potency expressed as 100 percent increase in right ventricular contractile force in dogs; CF(100) levels not obtained; CF(100) levels not obtained1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID73725Effective concentration for increasing potency force in guinea pig isolated left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID60584Inotropic potency expressed as 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1136161Agonist activity at Wistar rat brain GABA transporter assessed as tritium efflux by measuring [3H]GABA release at 2 uM after 20 to 30 mins by liquid scintillation counting analysis relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID73727Effective concentration for increasing potency rate in guinea pig isolated right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID58658Ionotropic selectivity expressed as change in heart rate for 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID57845Cardioselectivity expressed as change in blood pressure for 100% increase in right ventricular contractile force in dogs; CF(100) levels not obtained1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID25622Evaluated for the pKa value.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists.
AID1136160Agonist activity at Wistar rat brain serotonin transporter assessed as tritium efflux by measuring [3H]serotonin release at 2 uM after 20 to 30 mins by liquid scintillation counting analysis relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID64453Inhibition of binding of [3H]spiroperidol to Dopamine receptor D2 in rat striatal membranes2001Bioorganic & medicinal chemistry letters, Apr-09, Volume: 11, Issue:7
Cis- and trans-N-benzyl-octahydrobenzo[g]quinolines. Adrenergic and dopaminergic activity studies.
AID76919Compound was tested for or relative intrinsic activity in guinea pig isolated atrium left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID63119Evaluated for the percentage vasodilation in the renal artery produced by 3000 nmol administered intra-arterially; NA is No Antagonistic activity1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists.
AID1136158Agonist activity at Wistar rat striatum dopamine transporter assessed as tritium efflux by measuring [3H]dopamine release at 2 uM after 20 mins by liquid scintillation counting analysis relative to total tissue content1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID227265Percentage increase in contractile force was determined by the effect of DMI (desmethylimipramine, 1 mg/kg, iv) at 200 ug/kg1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID76920Compound was tested for relative intrinsic activity in guinea pig isolated atrium right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1803082CA Activity Assay from Article 10.3109/14756366.2011.591290: \\Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI.\\2012Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 27, Issue:3
Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (75.00)18.7374
1990's1 (8.33)18.2507
2000's1 (8.33)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.78 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3,4-dihydroxyphenylacetic acid
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.		1.9510catechols;
dihydroxyphenylacetic acid		human metabolite
homovanillic acid
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.		1.9510guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		2.0710monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
desipramine
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.		1.9610dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
n,n-di-n-propyldopamine
N,N-di-n-propyldopamine: RN given refers to parent cpd		1.9610catecholamine
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		1.9710benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
adtn
ADTN: RN given refers to parent cpd without isomeric designation; structure		3.3570
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		2.3620catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
nomifensine
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.		1.9510isoquinolinesdopamine uptake inhibitor
reserpine
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.		1.9510alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
dextroamphetamine
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.		1.97101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		2.3920aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		1.9710amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		2.6530naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
tropolone
Tropolone: A seven-membered aromatic ring compound. It is structurally related to a number of naturally occurring antifungal compounds (ANTIFUNGAL AGENTS).. tropolone : A cyclic ketone that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2. It is a toxin produced by the agricultural pathogen Burkholderia plantarii.		1.9510alpha-hydroxy ketone;
cyclic ketone;
enol		bacterial metabolite;
fungicide;
toxin
2-aminotetralin
2-aminotetralin: RN given refers to parent cpd without isomeric designation; structure		1.9510tetralins
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		1.9610catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
5,6-dihydroxy-2-dimethylaminotetralin
5,6-dihydroxy-2-dimethylaminotetralin: RN given refers to parent cpd; structure		1.9610tetralins
prolyl-leucyl-glycine
prolyl-leucyl-glycine: RN given refers to (L)-isomer		1.9710oligopeptide
asl 7022
ASL 7022: RN given refers to parent cpd; structure given in first source		1.9610
cocaine
Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.		1.9510benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials